Complete Switch to Everolimus in Long-Term Kidney Transplants: Evolution of the Renal Function

被引：3

作者：

Fernandez, A. ^{[1
]}

Marcen, R. ^{[1
]}

Galeano, C. ^{[1
]}

Caldes, S. ^{[1
]}

Amezquita, Y. ^{[1
]}

Villafruela, J. ^{[1
]}

Pascual, J. ^{[1
]}

Burgos, J. ^{[2
]}

Rodriguez-Mendiola, N. ^{[1
]}

Ortuno, J. ^{[1
]}

机构：

[1] Hosp Ramon & Cajal, Serv Nephrol, E-28034 Madrid, Spain

[2] Hosp Ramon & Cajal, Serv Urol, E-28034 Madrid, Spain

来源：

TRANSPLANTATION PROCEEDINGS | 2009年 / 41卷 / 06期

关键词：

CALCINEURIN INHIBITORS; CONVERSION; RECIPIENTS;

D O I：

10.1016/j.transproceed.2009.06.162

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Introduction. The use of M-tor inhibitors plus withdrawal of anticalcineurins after 3 months of posttransplantation is usually linked to improvements in renal function. The long-term effects of substitution of anticalcineurinis by everolimus remain unknown. The aim in this study was to evaluate the evolution of renal function and the proteinuria after a complete switch of long-term functioning allograft patients to everolimus. We treated 30 renal transplanted patients with everolimus, at a mean time posttransplantation of 123.8 +/- 74.2 months. The 27 patients, including 17 treated with tacrolimus and 10 with cyclosporine, who were controlled for at least 6 months were included in this study. Seventeen of them were diagnosed to display chronic allograft nephropathy (CAN). Results. The patients with CAN showed a basal creatinine of 1.81 +/- 0.4; with after a year, 1.61 +/- 0.38; and after 2 years, 1.56 +/- 0.49 mg/dL (P < .05). No significant changes were observed among patients without CAN: 1.1 +/- 0.32, 0.97 +/- 0.15, and 0.97 +/- 0.15 mg/dL, respectively. In CAN patients, the protein/creatinine quotient was: basal = 0.30 +/- 0.13, one year = 0.63 +/- 0.68, and 2 years = 0.48 +/- 0.34. In the other patients the values were 0.2 +/- 0.07, 0.73 +/- 0.7, and 0.32 +/- 0.17, respectively, after a late switch to everolimus. Conclusion. The improved renal function occured mainly inpatients with CAN. Patients who did not suffer from it showed a greater rise in proteinuria. Nevertheless, both groups experienced decreased proteinuria after 2 years.

引用

页码：2345 / 2347

页数：3

共 12 条

[1] Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus [J].

Bumbea, V ;

Kamar, N ;

Ribes, D ;

Esposito, L ;

Modesto, A ;

Guitard, J ;

Nasou, G ;

Durand, D ;

Rostaing, L .

NEPHROLOGY DIALYSIS TRANSPLANTATION, 2005, 20 (11) :2517-2523

[2] Proliferation signal inhibitors in transplantation: Questions at the cutting edge of everolimus therapy [J].

Chapman, J. R. ;

Valantine, H. ;

Albanell, J. ;

Arns, W. A. ;

Campistol, J. M. ;

Eisen, H. ;

Frigerio, M. ;

Lehmkuhl, H. ;

Marcen, R. ;

Morris, R. ;

Nashan, B. ;

Pascual, J. ;

Pohanka, E. ;

Segovia, J. ;

Zuckermann, A. .

TRANSPLANTATION PROCEEDINGS, 2007, 39 (10) :2937-2950

[3] Chronic renal allograft dysfunction [J].

Chapman, JR ;

O'Connell, PJ ;

Nankivell, BJ .

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2005, 16 (10) :3015-3026

[4] Use of proliferation signal inhibitors in non-melanoma skin cancer following renal transplantation [J].

de Fijter, J. W. .

NEPHROLOGY DIALYSIS TRANSPLANTATION, 2007, 22 :I23-I26

[5] Conversion from calcineurin inhibitors to everolimus in kidney transplant recipients with malignant neoplasia [J].

Fernandez, A. ;

Marcen, R. ;

Pascual, J. ;

Galeano, C. ;

Ocana, J. ;

Arellano, E. M. ;

Alfaro, C. ;

Villafruela, J. J. ;

Burgos, F. J. ;

Ortuno, J. .

TRANSPLANTATION PROCEEDINGS, 2006, 38 (08) :2453-2455

[6] Evaluation of the efficacy and safety of the conversion from a calcineurin inhibitor to an everolimus-based therapy in maintenance renal transplant patients [J].

Fructuoso, A. Sanchez ;

Millan, J. C. Ruiz San ;

Calvo, N. ;

Rodrigo, E. ;

Moreno, M. A. ;

Cotorruelo, J. ;

Conesa, J. ;

Gomez-Alamillo, C. ;

Arias, M. ;

Barrientos, A. .

TRANSPLANTATION PROCEEDINGS, 2007, 39 (07) :2148-2150

[7] Apoptosis and treatment of chronic allograft nephropathy with everolimus [J].

Lutz, J ;

Zou, HQ ;

Liu, SY ;

Antus, B ;

Heemann, U .

TRANSPLANTATION, 2003, 76 (03) :508-515

[8] Influence of immunosuppression on the prevalence of cancer after kidney transplantation [J].

Marcén, R ;

Pascual, J ;

Tato, AM ;

Teruel, JL ;

Villafruela, JJ ;

Fernández, M ;

Tenorio, M ;

Burgos, FJ ;

Ortuño, J .

TRANSPLANTATION PROCEEDINGS, 2003, 35 (05) :1714-1716

[9] Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies [J].

Mathew, T ;

Kreis, H ;

Friend, P .

CLINICAL TRANSPLANTATION, 2004, 18 (04) :446-449

[10] Calcineurin inhibitor nephrotoxicity: Longitudinal assessment by protocol histology [J].

Nankivell, BJ ;

Borrows, RJ ;

Fung, CLS ;

O'Connell, PJ ;

Chapman, JR ;

Allen, RDM .

TRANSPLANTATION, 2004, 78 (04) :557-565

← 1 2 →